Agile Therapeutics Releases Updated Investor Presentation
TipRanksApr 9 08:43 ET
Agile Therapeutics, Inc. (NASDAQ:AGRX) Q4 2023 Earnings Call Transcript
Yahoo FinanceApr 1 17:20 ET
Agile Therapeutics' Balancing Act: Funding Challenges Threaten R&D and Twirla Rollout
TipRanksMar 30 02:01 ET
Q4 2023 Agile Therapeutics Inc Earnings Call
Yahoo FinanceMar 28 23:34 ET
Earnings Call Summary | Agile Therapeutics(AGRX.US) Q4 2023 Earnings Conference
The following is a summary of the Agile Therapeutics, Inc. (AGRX) Q4 2023 Earnings Call Transcript:Financial Performance:Agile Therapeutics reported a full year net revenue of $19.6 million in 2023, a
moomoo AIMar 28 11:10 ET · Conference Call
Agile Therapeutics Q4 Adj $(1.46) Misses $(0.92) Estimate, Sales $3.62M Miss $4.07M Estimate
Agile Therapeutics (NASDAQ:AGRX) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(0.92) by 58.7 percent. This is a 83.78 percent increase over losses of
BenzingaMar 28 08:17 ET
Agile Therapeutics: Q4 Earnings Insights
Agile Therapeutics (OTC:AGRX) reported its Q4 earnings results on Thursday, March 28, 2024 at 08:05 AM.Here's what investors need to know about the announcement.EarningsAgile Therapeutics missed estim
BenzingaMar 28 08:15 ET
Press Release: Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand a
Dow JonesMar 28 08:06 ET
Agile Therapeutics 4Q Loss/Shr $1.51 >AGRX
Agile Therapeutics 4Q Loss/Shr $1.51 >AGRX
Dow JonesMar 28 08:05 ET
Agile Therapeutics 4Q Loss $4.47M >AGRX
Agile Therapeutics 4Q Loss $4.47M >AGRX
Dow JonesMar 28 08:05 ET
Notable Earnings Before Thursday's Open
Seeking AlphaMar 27 09:11 ET
Why Agile Therapeutics (AGRX) Stock Is Down 60%
Agile Therapeutics Inc (OTC:AGRX) shares are trading lower by 61% to $0.24 during Tuesday's session after the company announced the suspension of its trading on the Nasdaq effective Tuesday. The compa
BenzingaMar 26 12:18 ET
12 Health Care Stocks Moving In Monday's After-Market Session
GainersStoke Therapeutics (NASDAQ:STOK) shares increased by 77.7% to $11.55 during Monday's after-market session. The company's market cap stands at $515.7 million. As per the news, the Q4 earnings re
BenzingaMar 25 17:32 ET
Express News | Agile Therapeutics Shares Are Trading Lower After the Company Announced Suspension of Its Trading on the Nasdaq Will Be Effective Mar. 26
Moomoo 24/7Mar 25 16:49 ET
Agile Therapeutics Announces Delisting From Nasdaq
PRINCETON, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced that the Company has received a
GlobeNewswireMar 25 16:30 ET
Earnings Week Ahead: Walgreens Boots Alliance, Carnival, GameStop and More
Seeking AlphaMar 24 08:01 ET
Earnings Scheduled For March 22, 2024
Companies Reporting Before The Bell • Agile Therapeutics (NASDAQ:AGRX) is likely to report quarterly loss at $0.54 per share on revenue of $9.20 million. • 51 Talk Online Education (AMEX:COE) is proje
BenzingaMar 22 05:40 ET
Agile Therapeutics's Earnings: A Preview
Agile Therapeutics (NASDAQ:AGRX) is set to give its latest quarterly earnings report on Friday, 2024-03-22. Here's what investors need to know before the announcement.Analysts estimate that Agile Ther
BenzingaMar 21 10:00 ET
Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
PRINCETON, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before
GlobeNewswireMar 21 06:35 ET
Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before
GlobeNewswireMar 20 08:15 ET
No Data
No Data